UNSPSC 51351511: Megestrol acetate

This classification denotes a therapeutic progestin with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TJ2M0FR8ES, chemically known as pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- but generally known as megestrol acetate, which bears US NIH Compound Identifier 4048. European Medicines Agency schedules Megestrol acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03117MIG. Most nations schedule megestrol acetate under HS 29372300 and SITC 54153.

As of Q4 2014, MEGESTROL ACETATE remains the US FDA Preferred Term for this commodity. Megestrol acetate bears US NLM identifiers UMLS ID C0065879 and NCI Concept Code C1156. SMILES: O(C1(C2(C(C3C(CC2)C2(C(=CC(=O)CC2)C(=C3)C)C)CC1)C)C(=O)C)C(=O)C.

UNSPSC 51351511 Megestrol acetate is a Commodity code capturing pharmaceutical products supplied through cooperative purchasing vehicles to state and local government facilities. State and local governments procure this and related generic pharmaceuticals through multistate cooperative agreements that consolidate demand across participating jurisdictions, manage supply chain logistics through authorized wholesalers, and establish tiered pricing structures tied to competitive bidding on volume commitments. The work involves pharmaceutical manufacturers supplying products with full regulatory compliance documentation, maintaining wholesaler relationships, and meeting strict cGMP and Drug Supply Chain Security Act (DSCSA) requirements. Issuing bodies include state procurement offices administering multistate cooperatives and participating state and local government agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary recent buyer soliciting under this code.

The Minnesota Department of Administration's Office of State Procurement issued an RFP (Solicitation S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across MMCAP member states including Oregon. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026, and resulting agreements effective July 1, 2026. The procurement weights price competitiveness at seventy-five percent, with smaller weights on fixed pricing, administrative compliance, EDI capability, and acceptance of a three percent administrative fee. Vendors must maintain commercial general liability insurance of five million dollars per occurrence, network security and privacy liability of two million dollars, and professional liability of two million dollars, and all products must comply with FDA requirements with minimum six-month shelf lives. The contract term is two years for new responders with optional extensions, while incumbent vendors' amendments align with existing agreement expiration dates through June 30, 2028.